Editas Medicine, Inc.EDITEarnings & Financial Report
Editas Medicine, Inc.,, is a clinical-stage biotechnology company which is developing therapies for rare diseases based on CRISPR gene editing technology. Editas headquarters is located in Cambridge, Massachusetts and has facilities in Boulder, Colorado.
Revenue
$513.0K
Gross Profit
N/A
Operating Profit
$-71.9M
Net Profit
$-67.6M
Gross Margin
N/A
Operating Margin
-14016.2%
Net Margin
-13178.8%
YoY Growth
-82.2%
EPS
$-0.82
Editas Medicine, Inc. Q2 FY2024 Financial Summary
Editas Medicine, Inc. reported revenue of $513.0K (down 82.2% YoY) for Q2 FY2024, with a net profit of $-67.6M (down 67.8% YoY) (-13178.8% margin).
Key Financial Metrics
| Total Revenue | $513.0K |
|---|---|
| Net Profit | $-67.6M |
| Gross Margin | N/A |
| Operating Margin | -14016.2% |
| Report Period | Q2 FY2024 |
Editas Medicine, Inc. Annual Revenue by Year
Editas Medicine, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $40.5M).
| Year | Annual Revenue |
|---|---|
| 2025 | $40.5M |
| 2024 | $32.3M |
| 2023 | $78.1M |
| 2022 | $19.7M |
Editas Medicine, Inc. Quarterly Revenue & Net Profit History
Editas Medicine, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $24.7M | -19.2% | $-5.6M | -22.7% |
| Q3 FY2025 | $7.5M | +12265.6% | $-25.1M | -333.0% |
| Q2 FY2025 | $3.6M | +597.5% | $-53.2M | -1487.8% |
| Q1 FY2025 | $4.7M | +310.4% | $-76.1M | -1633.5% |
| Q4 FY2024 | $30.6M | -49.0% | $-45.4M | -148.3% |
| Q3 FY2024 | $61.0K | -98.9% | $-62.1M | -101870.5% |
| Q2 FY2024 | $513.0K | -82.2% | $-67.6M | -13178.8% |
| Q1 FY2024 | $1.1M | -88.5% | $-62.0M | -5458.1% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1M | $513000 | $61000 | $30.6M | $4.7M | $3.6M | $7.5M | $24.7M |
| YoY Growth | -88.5% | -82.2% | -98.9% | -49.0% | 310.4% | 597.5% | 12265.6% | -19.2% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $440.3M | $384.8M | $327.6M | $341.6M | $263.7M | $210.6M | $201.8M | $186.5M |
| Liabilities | $145.9M | $152.8M | $151.9M | $207.3M | $201.2M | $191.4M | $188.3M | $159.2M |
| Equity | $294.4M | $232.0M | $175.6M | $134.3M | $62.4M | $19.2M | $13.5M | $27.3M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-49.9M | $-57.1M | $-52.6M | $-50.8M | $-47.8M | $-50.2M | $-30.8M | $-36.4M |